Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > 2nd ADC toxicity summit

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Apr 30, 2024 11:14am

56 Views

Post# 36014833

RE:2nd ADC toxicity summit

Scarlet1967, I noticed Thera’s time slot (10AM on day one) and it appears to be a decent one, is that correct?

scarlet1967 wrote:
https://storage.pardot.com/448062/1713868707LeQ1wadz/HW240322_46355_2nd_ADC_Toxicity_Summit_brochure_v8.pdf

"Targeting Sortilin (SORT1) to Unlock the Potential of Peptide Drug Conjugates (PDCs) in Oncology: Rapid Internalization within Minutes w

Unique Multimodal MOA & Safety Profile

Understand the rationale for targeting the SORT1 receptor in cancer

Discuss the unique toxicity profile of sudocetaxel zendusortide (TH1902), the lead PL from Theratechnologies' SORT1+ Technology ™ platform, that differs substantially fro the safety profile of taxanes, due to the multimodal MOA of the conjugate and the low levels of free circulating docetaxel

Discuss how this multifaceted MOA with improved safety profile can lead to prolonge regression of disease and enable combinations with ADCs, PDCs and other anti-can therapies

Discuss the ongoing phase I clinical development of sudocetaxel zendusortide, focus on dose optimization"

So Christian is speaking at this summit this time the focus is toxicity/ safety profile of the drug!

Have they had more human data so far as the issue with the drug and abrupt stop of the clinical trial initially was because of toxicity/safety concerns??